Amar Kelkar

23PUBLICATIONS
144CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHaematological tumoursGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (23)

|Apr 30, 2026
Randomized, Placebo-Controlled Trial of B-Cell Depletion for Prevention of Corticosteroid-Requiring Chronic Graft-Versus-Host Disease.

|Feb 25, 2026
WBC Growth Factors: ASCO Guideline Update.

Bishal Gyawali, Kari Bohlke, Jana K Dickter

|Feb 24, 2026
No clear benefit of cellular therapy consolidation for patients achieving remission after post-HCT AML relapse.

H Moses Murdock, Haesook T Kim, Katie Maurer

|Jan 26, 2026
Baseline IPSS-M vs pretransplant risk downstaging as prognostic determinants in MDS undergoing allogeneic transplantation.

Luis E Aguirre, Haesook T Kim, Hany Elmariah

|Jan 21, 2026
Is It Time to Move Beyond Graft-Versus-Host Disease-Free, Relapse-Free Survival as a Primary End Point in Clinical Trials for Hematopoietic Cell Transplantation?

Amar H Kelkar, Gregory A Abel, Corey S Cutler

|Dec 05, 2025
Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor-risk MDS/AML.

Jacqueline S Garcia, Haesook T Kim, H Moses Murdock

Pageof 4

Frequent Collaborators

4 joint publications

Jacqueline S Garcia

4 joint publications

Haesook T Kim

4 joint publications

Corey S Cutler

3 joint publications

Evan C Chen